Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)

被引：25

作者：

Cornelissen, Robin ^{[1
]}

Prelaj, Arsela ^{[2
,3
]}

Sun, Sophie ^{[4
]}

Baik, Christina ^{[5
]}

Wollner, Mirjana ^{[6
]}

Haura, Eric B. ^{[7
]}

Mamdani, Hirva ^{[8
,9
]}

Riess, Jonathan W. ^{[10
,11
]}

Cappuzzo, Federico ^{[12
]}

Garassino, Marina C. ^{[13
]}

Heymach, John V. ^{[14
]}

Socinski, Mark A. ^{[15
]}

Leu, Szu-Yun ^{[16
]}

Bhat, Gajanan ^{[16
]}

Lebel, Francois ^{[16
]}

Le, Xiuning ^{[14
]}

机构：

[1] Erasmus MC Canc Inst, Pulm Med, Rotterdam, Netherlands

[2] Fdn Ist Ricovero & Cura Carattere Sci IRCCS, Ist Nazl Tumori Milano, Med Oncol, Milan, Italy

[3] Politecn Milan, Dept Elect Informat & Bioengn, Milan, Italy

[4] British Columbia Canc Ctr, Med Oncol, Vancouver, BC, Canada

[5] Seattle Canc Ctr Alliance, Seattle, WA USA

[6] Rambam Hlth Care Campus, Med Oncol, Haifa, Israel

[7] H Lee Moffitt Canc Ctr & Res Inst, Thorac Oncol, Tampa, FL USA

[8] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI USA

[9] Barbara Ann Karmanos Canc Inst, Detroit, MI USA

[10] Univ Calif Davis, Sch Med, Div Hematol & Oncol, Dept Internal Med, Sacramento, CA USA

[11] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA USA

[12] Natl Canc Inst IRCCS Regina Elena, Dept Oncol, Rome, Italy

[13] Univ Chicago, Hematol Oncol Sect, Dept Med, Knapp Ctr Biomed Discovery, Chicago, IL USA

[14] Univ Texas MD Anderson Canc Ctr Houston, Dept Thorac Head & Neck Med Oncol, Houston, TX USA

[15] AdventHlth Canc Inst, Thorac Oncol Program, Orlando, FL USA

[16] Spectrum Pharmaceut, Res Dev, Irvine, CA USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 08期

关键词：

KINASE DOMAIN; ANTITUMOR-ACTIVITY; SOMATIC MUTATIONS; CANCER; EGFR; HM781-36B; INHIBITOR;

D O I：

10.1016/j.jtho.2023.03.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1031 / 1041

页数：11

共 50 条

[1] Efficacy and safety of poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4)
Cornelissen, R.
Sun, S.
Wollner, M.
Garassino, M. C. C.
Prelaj, A.
Haura, E. B.
Piotrowska, Z.
Goldman, J. W.
Socinski, M.
Dreling, L.
Bhat, G.
Lebel, F.
Le, X.
ANNALS OF ONCOLOGY, 2021, 32 : S1324 - S1324
[2] Efficacy and safety of poziotinib in treatment-naive HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
Sun, S.
Prelaj, A.
Baik, C.
Le, X.
Garassino, M.
Wollner, M.
Haura, E.
Piotrowska, Z.
Socinski, M.
Dreiling, L.
Bhat, G.
Lebel, F.
Cornelissen, R.
ANNALS OF ONCOLOGY, 2022, 33 : S13 - S13
[3] ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
Socinski, M. A.
Cornelissen, R.
Garassino, M. C.
Clarke, J.
Tchekmedyian, N.
Molina, J.
Goldman, J. W.
Bhat, G.
Lebel, F.
Le, X.
ANNALS OF ONCOLOGY, 2020, 31 : S1188 - S1188
[4] Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib
不详
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[5] Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
Le, Xiuning
Cornelissen, Robin
Garassino, Marina
Clarke, Jeffrey M.
Tchekmedyian, Nishan
Goldman, Jonathan W.
Leu, Szu-Yun
Bhat, Gajanan
Lebel, Francois
Heymach, John, V
Socinski, Mark A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (07) : 710 - 718
[6] Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5).
Le, Xiuning
Shum, Elaine
Suga, Jennifer M.
Brahmer, Julie R.
Dooms, Christophe
Mamdani, Hirva
Nechushtan, Hovav
Riess, Jonathan W.
Spira, Alexander
Barrett, John A.
Dreiling, Lyndah K.
Socinski, Mark
CANCER RESEARCH, 2021, 81 (13)
[7] A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
Heymach, J.
Negrao, M.
Robichaux, J.
Carter, B.
Patel, A.
Altan, M.
Gibbons, D.
Fossella, F.
Simon, G.
Lam, V.
Blumenschein, G.
Tsao, A.
Kurie, J.
Mott, F.
Jenkins, D.
Mack, D.
Feng, L.
Roeck, B.
Yang, Z.
Papadimitrakopoulou, V.
Elamin, Y.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S323 - S324
[8] Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients with NSCLC harboring HER2 exon 20 insertion mutations
Thiagalingam, Arunthi
Lakshmikanthan, Sribalaji
Mak, Allysia J.
Shell, Scott A.
Leu, Sharon
Washington, Rocky
Dreiling, Lyndah
Bhat, Gajanan
Lebel, Francois
Barrett, John A.
CANCER RESEARCH, 2022, 82 (12)
[9] Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
Ren, Shengxiang
He, Jianxing
Fang, Yong
Chen, Gongyan
Ma, Zhiyong
Chen, Jianhua
Guo, Renhua
Lin, Xiaoyan
Yao, Yu
Wu, Gang
Wang, Quanren
Zhou, Caicun
JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (05):
[10] Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing
Robichaux, Jacqulyne P.
Elamin, Yasir Y.
Tan, Zhi
Negrao, Marelo Vailati
Routbort, Mark
Roeck, Brent
Li, Shuai
Liu, Shengwu
Chen, Ting
Ahnert, Jordi Rodon
Diao, Lixia
Nilsson, Monique B.
Zhang, Shuxing
Yang, Zane
Wang, Jing
Meric-Bernstam, Funda
Wong, Kwok-Kin
Heymach, John V.
CANCER RESEARCH, 2018, 78 (13)

← 1 2 3 4 5 →